SU5416 Flk-1/KDR signaling pathway angiogenesis inhibitor: Phase I data; Phase I/II

SUGN said that interim data from a Phase I trial showed anecdotal evidence of activity, as well as tolerability. In the dose-escalation study, 60 patients with advanced malignancies have been treated ...